BRIASETA

This brand name is authorized in Estonia, Ireland

Active ingredients

The drug BRIASETA contains one active pharmaceutical ingredient (API):

1 Ambrisentan UNII HW6NV07QEC - AMBRISENTAN

Ambrisentan is an orally active, propanoic acid-class, ERA selective for the endothelin A (ETA) receptor. Endothelin plays a significant role in the pathophysiology of PAH. Read about Ambrisentan

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BRIASETA Film-coated tablet	Health Products Regulatory Authority (IE)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C02KX02	Ambrisentan	C Cardiovascular system → C02 Antihypertensives → C02K Other antihypertensives → C02KX Antihypertensives for pulmonary arterial hypertension
Discover more medicines within C02KX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1827851, 1827862, 1827873, 1827884, 1827895, 1827907, 1827918, 1827929